nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—ABCB1—kidney cancer	0.322	1	CbGaD
Linagliptin—ABCB1—Temsirolimus—kidney cancer	0.0684	0.134	CbGbCtD
Linagliptin—CYP3A4—Everolimus—kidney cancer	0.0607	0.119	CbGbCtD
Linagliptin—CYP3A4—Temsirolimus—kidney cancer	0.041	0.0802	CbGbCtD
Linagliptin—ABCB1—Pazopanib—kidney cancer	0.0359	0.0703	CbGbCtD
Linagliptin—ABCB1—Dactinomycin—kidney cancer	0.0329	0.0643	CbGbCtD
Linagliptin—ABCB1—Gemcitabine—kidney cancer	0.026	0.0509	CbGbCtD
Linagliptin—ABCB1—Erlotinib—kidney cancer	0.0256	0.0502	CbGbCtD
Linagliptin—ABCB1—Paclitaxel—kidney cancer	0.0235	0.046	CbGbCtD
Linagliptin—CYP3A4—Pazopanib—kidney cancer	0.0215	0.0422	CbGbCtD
Linagliptin—ABCB1—Sorafenib—kidney cancer	0.0209	0.0408	CbGbCtD
Linagliptin—ABCB1—Vinblastine—kidney cancer	0.0206	0.0403	CbGbCtD
Linagliptin—ABCB1—Vincristine—kidney cancer	0.0202	0.0396	CbGbCtD
Linagliptin—ABCB1—Sunitinib—kidney cancer	0.0169	0.0331	CbGbCtD
Linagliptin—CYP3A4—Erlotinib—kidney cancer	0.0154	0.0301	CbGbCtD
Linagliptin—CYP3A4—Paclitaxel—kidney cancer	0.0141	0.0275	CbGbCtD
Linagliptin—ABCB1—Doxorubicin—kidney cancer	0.0127	0.0248	CbGbCtD
Linagliptin—CYP3A4—Sorafenib—kidney cancer	0.0125	0.0245	CbGbCtD
Linagliptin—CYP3A4—Vinblastine—kidney cancer	0.0123	0.0241	CbGbCtD
Linagliptin—CYP3A4—Vincristine—kidney cancer	0.0121	0.0237	CbGbCtD
Linagliptin—CYP3A4—Sunitinib—kidney cancer	0.0101	0.0198	CbGbCtD
Linagliptin—CYP3A4—Doxorubicin—kidney cancer	0.00758	0.0148	CbGbCtD
Linagliptin—DPP4—Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)—PAX6—kidney cancer	0.00241	0.122	CbGpPWpGaD
Linagliptin—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—PAX6—kidney cancer	0.00178	0.0903	CbGpPWpGaD
Linagliptin—DPP4—Incretin synthesis, secretion, and inactivation—PAX6—kidney cancer	0.00158	0.0803	CbGpPWpGaD
Linagliptin—Nasopharyngitis—Sorafenib—kidney cancer	0.000755	0.00521	CcSEcCtD
Linagliptin—Infestation NOS—Everolimus—kidney cancer	0.00075	0.00517	CcSEcCtD
Linagliptin—Infestation—Everolimus—kidney cancer	0.00075	0.00517	CcSEcCtD
Linagliptin—Malnutrition—Pazopanib—kidney cancer	0.000742	0.00512	CcSEcCtD
Linagliptin—DPP4—Peptide hormone metabolism—MME—kidney cancer	0.000734	0.0373	CbGpPWpGaD
Linagliptin—Urinary tract infection—Everolimus—kidney cancer	0.000729	0.00503	CcSEcCtD
Linagliptin—Nasopharyngitis—Sunitinib—kidney cancer	0.000727	0.00501	CcSEcCtD
Linagliptin—Infestation NOS—Erlotinib—kidney cancer	0.000724	0.00499	CcSEcCtD
Linagliptin—Infestation—Erlotinib—kidney cancer	0.000724	0.00499	CcSEcCtD
Linagliptin—Angioedema—Temsirolimus—kidney cancer	0.00072	0.00496	CcSEcCtD
Linagliptin—Skin exfoliation—Paclitaxel—kidney cancer	0.000718	0.00495	CcSEcCtD
Linagliptin—Pancreatitis—Sorafenib—kidney cancer	0.000716	0.00493	CcSEcCtD
Linagliptin—Pancreatitis—Sunitinib—kidney cancer	0.000689	0.00475	CcSEcCtD
Linagliptin—Pain in extremity—Vincristine—kidney cancer	0.000687	0.00474	CcSEcCtD
Linagliptin—Cough—Temsirolimus—kidney cancer	0.000687	0.00474	CcSEcCtD
Linagliptin—Myalgia—Temsirolimus—kidney cancer	0.000671	0.00462	CcSEcCtD
Linagliptin—Arthralgia—Temsirolimus—kidney cancer	0.000671	0.00462	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Temsirolimus—kidney cancer	0.000666	0.00459	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Sunitinib—kidney cancer	0.000653	0.0045	CcSEcCtD
Linagliptin—Infestation NOS—Sorafenib—kidney cancer	0.000651	0.00449	CcSEcCtD
Linagliptin—Infestation—Sorafenib—kidney cancer	0.000651	0.00449	CcSEcCtD
Linagliptin—Cough—Pazopanib—kidney cancer	0.000648	0.00446	CcSEcCtD
Linagliptin—Anaphylactic shock—Temsirolimus—kidney cancer	0.000643	0.00443	CcSEcCtD
Linagliptin—Infection—Temsirolimus—kidney cancer	0.000639	0.0044	CcSEcCtD
Linagliptin—Myalgia—Pazopanib—kidney cancer	0.000632	0.00436	CcSEcCtD
Linagliptin—Arthralgia—Pazopanib—kidney cancer	0.000632	0.00436	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Pazopanib—kidney cancer	0.000627	0.00433	CcSEcCtD
Linagliptin—Infestation NOS—Sunitinib—kidney cancer	0.000626	0.00432	CcSEcCtD
Linagliptin—Infestation—Sunitinib—kidney cancer	0.000626	0.00432	CcSEcCtD
Linagliptin—Skin disorder—Temsirolimus—kidney cancer	0.000624	0.00431	CcSEcCtD
Linagliptin—Urinary tract infection—Sunitinib—kidney cancer	0.000609	0.0042	CcSEcCtD
Linagliptin—Immune system disorder—Everolimus—kidney cancer	0.000608	0.00419	CcSEcCtD
Linagliptin—Mediastinal disorder—Everolimus—kidney cancer	0.000607	0.00418	CcSEcCtD
Linagliptin—Infection—Pazopanib—kidney cancer	0.000602	0.00415	CcSEcCtD
Linagliptin—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—CTNNB1—kidney cancer	0.0006	0.0305	CbGpPWpGaD
Linagliptin—CYP3A4—Aflatoxin activation and detoxification—ACY1—kidney cancer	0.000595	0.0302	CbGpPWpGaD
Linagliptin—Skin exfoliation—Capecitabine—kidney cancer	0.000589	0.00406	CcSEcCtD
Linagliptin—Skin disorder—Pazopanib—kidney cancer	0.000588	0.00406	CcSEcCtD
Linagliptin—Malnutrition—Everolimus—kidney cancer	0.000586	0.00404	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Temsirolimus—kidney cancer	0.000586	0.00404	CcSEcCtD
Linagliptin—Mediastinal disorder—Erlotinib—kidney cancer	0.000585	0.00404	CcSEcCtD
Linagliptin—Back pain—Everolimus—kidney cancer	0.000567	0.00391	CcSEcCtD
Linagliptin—Malnutrition—Erlotinib—kidney cancer	0.000565	0.0039	CcSEcCtD
Linagliptin—DPP4—Peptide hormone metabolism—ACHE—kidney cancer	0.000563	0.0286	CbGpPWpGaD
Linagliptin—Hypoglycaemia—Paclitaxel—kidney cancer	0.000559	0.00386	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Temsirolimus—kidney cancer	0.000555	0.00383	CcSEcCtD
Linagliptin—Hyperlipidaemia—Doxorubicin—kidney cancer	0.000552	0.00381	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Pazopanib—kidney cancer	0.000552	0.0038	CcSEcCtD
Linagliptin—Constipation—Temsirolimus—kidney cancer	0.00055	0.00379	CcSEcCtD
Linagliptin—Back pain—Erlotinib—kidney cancer	0.000547	0.00377	CcSEcCtD
Linagliptin—Pain in extremity—Paclitaxel—kidney cancer	0.000546	0.00376	CcSEcCtD
Linagliptin—DPP4—Peptide hormone metabolism—PAX6—kidney cancer	0.000536	0.0272	CbGpPWpGaD
Linagliptin—Angioedema—Everolimus—kidney cancer	0.000535	0.00369	CcSEcCtD
Linagliptin—DPP4—Incretin synthesis, secretion, and inactivation—CTNNB1—kidney cancer	0.000533	0.0271	CbGpPWpGaD
Linagliptin—DPP4—Peptide hormone metabolism—CTSD—kidney cancer	0.000533	0.0271	CbGpPWpGaD
Linagliptin—Immune system disorder—Sorafenib—kidney cancer	0.000528	0.00364	CcSEcCtD
Linagliptin—Mediastinal disorder—Sorafenib—kidney cancer	0.000527	0.00363	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Pazopanib—kidney cancer	0.000523	0.00361	CcSEcCtD
Linagliptin—Diabetes mellitus—Capecitabine—kidney cancer	0.000515	0.00355	CcSEcCtD
Linagliptin—Cough—Everolimus—kidney cancer	0.000511	0.00353	CcSEcCtD
Linagliptin—Malnutrition—Sorafenib—kidney cancer	0.000509	0.00351	CcSEcCtD
Linagliptin—Immune system disorder—Sunitinib—kidney cancer	0.000508	0.0035	CcSEcCtD
Linagliptin—Mediastinal disorder—Sunitinib—kidney cancer	0.000507	0.00349	CcSEcCtD
Linagliptin—Myalgia—Everolimus—kidney cancer	0.000499	0.00344	CcSEcCtD
Linagliptin—Arthralgia—Everolimus—kidney cancer	0.000499	0.00344	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	0.000495	0.00342	CcSEcCtD
Linagliptin—Cough—Erlotinib—kidney cancer	0.000493	0.0034	CcSEcCtD
Linagliptin—DPP4—Peptide hormone metabolism—BCHE—kidney cancer	0.00049	0.0249	CbGpPWpGaD
Linagliptin—Malnutrition—Sunitinib—kidney cancer	0.000489	0.00337	CcSEcCtD
Linagliptin—Nasopharyngitis—Paclitaxel—kidney cancer	0.000488	0.00337	CcSEcCtD
Linagliptin—Arthralgia—Erlotinib—kidney cancer	0.000481	0.00332	CcSEcCtD
Linagliptin—Myalgia—Erlotinib—kidney cancer	0.000481	0.00332	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	0.000478	0.0033	CcSEcCtD
Linagliptin—Infection—Everolimus—kidney cancer	0.000475	0.00328	CcSEcCtD
Linagliptin—Hypersensitivity—Temsirolimus—kidney cancer	0.000474	0.00327	CcSEcCtD
Linagliptin—Back pain—Sunitinib—kidney cancer	0.000473	0.00326	CcSEcCtD
Linagliptin—Angioedema—Sorafenib—kidney cancer	0.000465	0.0032	CcSEcCtD
Linagliptin—Skin disorder—Everolimus—kidney cancer	0.000465	0.0032	CcSEcCtD
Linagliptin—Pancreatitis—Paclitaxel—kidney cancer	0.000463	0.00319	CcSEcCtD
Linagliptin—Infection—Erlotinib—kidney cancer	0.000458	0.00316	CcSEcCtD
Linagliptin—Skin disorder—Erlotinib—kidney cancer	0.000448	0.00309	CcSEcCtD
Linagliptin—Pain in extremity—Capecitabine—kidney cancer	0.000448	0.00309	CcSEcCtD
Linagliptin—Angioedema—Sunitinib—kidney cancer	0.000447	0.00308	CcSEcCtD
Linagliptin—Cough—Sorafenib—kidney cancer	0.000444	0.00306	CcSEcCtD
Linagliptin—Diarrhoea—Temsirolimus—kidney cancer	0.00044	0.00303	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Paclitaxel—kidney cancer	0.000439	0.00302	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Everolimus—kidney cancer	0.000436	0.003	CcSEcCtD
Linagliptin—Arthralgia—Sorafenib—kidney cancer	0.000433	0.00299	CcSEcCtD
Linagliptin—Myalgia—Sorafenib—kidney cancer	0.000433	0.00299	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.00043	0.00297	CcSEcCtD
Linagliptin—Weight increased—Paclitaxel—kidney cancer	0.000429	0.00296	CcSEcCtD
Linagliptin—Mediastinal disorder—Vincristine—kidney cancer	0.000429	0.00295	CcSEcCtD
Linagliptin—Cough—Sunitinib—kidney cancer	0.000427	0.00294	CcSEcCtD
Linagliptin—Infestation—Paclitaxel—kidney cancer	0.000421	0.0029	CcSEcCtD
Linagliptin—Infestation NOS—Paclitaxel—kidney cancer	0.000421	0.0029	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Erlotinib—kidney cancer	0.00042	0.0029	CcSEcCtD
Linagliptin—Arthralgia—Sunitinib—kidney cancer	0.000417	0.00287	CcSEcCtD
Linagliptin—Myalgia—Sunitinib—kidney cancer	0.000417	0.00287	CcSEcCtD
Linagliptin—Anaphylactic shock—Sorafenib—kidney cancer	0.000415	0.00286	CcSEcCtD
Linagliptin—Diarrhoea—Pazopanib—kidney cancer	0.000414	0.00286	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000414	0.00285	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Everolimus—kidney cancer	0.000413	0.00285	CcSEcCtD
Linagliptin—Infection—Sorafenib—kidney cancer	0.000412	0.00284	CcSEcCtD
Linagliptin—Constipation—Vinblastine—kidney cancer	0.000411	0.00283	CcSEcCtD
Linagliptin—Urinary tract infection—Paclitaxel—kidney cancer	0.000409	0.00282	CcSEcCtD
Linagliptin—Constipation—Everolimus—kidney cancer	0.000409	0.00282	CcSEcCtD
Linagliptin—Immune system disorder—Gemcitabine—kidney cancer	0.000408	0.00281	CcSEcCtD
Linagliptin—Mediastinal disorder—Gemcitabine—kidney cancer	0.000407	0.0028	CcSEcCtD
Linagliptin—Rash—Temsirolimus—kidney cancer	0.000405	0.00279	CcSEcCtD
Linagliptin—Dermatitis—Temsirolimus—kidney cancer	0.000405	0.00279	CcSEcCtD
Linagliptin—Skin disorder—Sorafenib—kidney cancer	0.000403	0.00278	CcSEcCtD
Linagliptin—Headache—Temsirolimus—kidney cancer	0.000403	0.00278	CcSEcCtD
Linagliptin—Nasopharyngitis—Capecitabine—kidney cancer	0.000401	0.00276	CcSEcCtD
Linagliptin—Back pain—Vincristine—kidney cancer	0.0004	0.00276	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000398	0.00275	CcSEcCtD
Linagliptin—Infection—Sunitinib—kidney cancer	0.000397	0.00274	CcSEcCtD
Linagliptin—Constipation—Erlotinib—kidney cancer	0.000395	0.00272	CcSEcCtD
Linagliptin—Myalgia—Dactinomycin—kidney cancer	0.000394	0.00272	CcSEcCtD
Linagliptin—Skin disorder—Sunitinib—kidney cancer	0.000388	0.00268	CcSEcCtD
Linagliptin—Rash—Pazopanib—kidney cancer	0.000382	0.00263	CcSEcCtD
Linagliptin—Dermatitis—Pazopanib—kidney cancer	0.000382	0.00263	CcSEcCtD
Linagliptin—Back pain—Gemcitabine—kidney cancer	0.00038	0.00262	CcSEcCtD
Linagliptin—Skin exfoliation—Doxorubicin—kidney cancer	0.00038	0.00262	CcSEcCtD
Linagliptin—Headache—Pazopanib—kidney cancer	0.000379	0.00262	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Sorafenib—kidney cancer	0.000378	0.00261	CcSEcCtD
Linagliptin—Infection—Dactinomycin—kidney cancer	0.000376	0.00259	CcSEcCtD
Linagliptin—CYP3A4—Fatty Acid Omega Oxidation—ALDH1A1—kidney cancer	0.000374	0.019	CbGpPWpGaD
Linagliptin—Musculoskeletal discomfort—Sunitinib—kidney cancer	0.000364	0.00251	CcSEcCtD
Linagliptin—CYP3A4—urine—kidney cancer	0.000362	0.187	CbGeAlD
Linagliptin—Upper respiratory tract infection—Capecitabine—kidney cancer	0.00036	0.00248	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000358	0.00247	CcSEcCtD
Linagliptin—Constipation—Sorafenib—kidney cancer	0.000355	0.00245	CcSEcCtD
Linagliptin—Hypersensitivity—Vinblastine—kidney cancer	0.000354	0.00244	CcSEcCtD
Linagliptin—Myalgia—Vincristine—kidney cancer	0.000352	0.00243	CcSEcCtD
Linagliptin—Weight increased—Capecitabine—kidney cancer	0.000352	0.00243	CcSEcCtD
Linagliptin—Hypersensitivity—Everolimus—kidney cancer	0.000352	0.00243	CcSEcCtD
Linagliptin—Infestation—Capecitabine—kidney cancer	0.000345	0.00238	CcSEcCtD
Linagliptin—Infestation NOS—Capecitabine—kidney cancer	0.000345	0.00238	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000345	0.00238	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Dactinomycin—kidney cancer	0.000345	0.00238	CcSEcCtD
Linagliptin—Cough—Gemcitabine—kidney cancer	0.000343	0.00236	CcSEcCtD
Linagliptin—Constipation—Sunitinib—kidney cancer	0.000342	0.00236	CcSEcCtD
Linagliptin—Immune system disorder—Paclitaxel—kidney cancer	0.000341	0.00235	CcSEcCtD
Linagliptin—Mediastinal disorder—Paclitaxel—kidney cancer	0.00034	0.00235	CcSEcCtD
Linagliptin—Anaphylactic shock—Vincristine—kidney cancer	0.000338	0.00233	CcSEcCtD
Linagliptin—Infection—Vincristine—kidney cancer	0.000336	0.00231	CcSEcCtD
Linagliptin—Urinary tract infection—Capecitabine—kidney cancer	0.000336	0.00231	CcSEcCtD
Linagliptin—Myalgia—Gemcitabine—kidney cancer	0.000334	0.00231	CcSEcCtD
Linagliptin—Arthralgia—Gemcitabine—kidney cancer	0.000334	0.00231	CcSEcCtD
Linagliptin—Diabetes mellitus—Doxorubicin—kidney cancer	0.000332	0.00229	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000332	0.00229	CcSEcCtD
Linagliptin—Urticaria—Sorafenib—kidney cancer	0.00033	0.00227	CcSEcCtD
Linagliptin—Malnutrition—Paclitaxel—kidney cancer	0.000329	0.00227	CcSEcCtD
Linagliptin—Diarrhoea—Vinblastine—kidney cancer	0.000328	0.00226	CcSEcCtD
Linagliptin—Diarrhoea—Everolimus—kidney cancer	0.000327	0.00226	CcSEcCtD
Linagliptin—Anaphylactic shock—Gemcitabine—kidney cancer	0.000321	0.00221	CcSEcCtD
Linagliptin—Infection—Gemcitabine—kidney cancer	0.000318	0.0022	CcSEcCtD
Linagliptin—Back pain—Paclitaxel—kidney cancer	0.000318	0.00219	CcSEcCtD
Linagliptin—Diarrhoea—Erlotinib—kidney cancer	0.000316	0.00218	CcSEcCtD
Linagliptin—Skin disorder—Gemcitabine—kidney cancer	0.000311	0.00215	CcSEcCtD
Linagliptin—ABCB1—Allograft Rejection—HARS—kidney cancer	0.000309	0.0157	CbGpPWpGaD
Linagliptin—Musculoskeletal discomfort—Vincristine—kidney cancer	0.000308	0.00212	CcSEcCtD
Linagliptin—Hypersensitivity—Sorafenib—kidney cancer	0.000306	0.00211	CcSEcCtD
Linagliptin—Rash—Everolimus—kidney cancer	0.000302	0.00208	CcSEcCtD
Linagliptin—Dermatitis—Everolimus—kidney cancer	0.000301	0.00208	CcSEcCtD
Linagliptin—Headache—Vinblastine—kidney cancer	0.000301	0.00207	CcSEcCtD
Linagliptin—Angioedema—Paclitaxel—kidney cancer	0.0003	0.00207	CcSEcCtD
Linagliptin—Headache—Everolimus—kidney cancer	0.0003	0.00207	CcSEcCtD
Linagliptin—DPP4—nephron tubule—kidney cancer	0.000299	0.155	CbGeAlD
Linagliptin—Hypoglycaemia—Doxorubicin—kidney cancer	0.000296	0.00204	CcSEcCtD
Linagliptin—Hypersensitivity—Sunitinib—kidney cancer	0.000294	0.00203	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000292	0.00201	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Vincristine—kidney cancer	0.000292	0.00201	CcSEcCtD
Linagliptin—Rash—Erlotinib—kidney cancer	0.000291	0.00201	CcSEcCtD
Linagliptin—Dermatitis—Erlotinib—kidney cancer	0.000291	0.002	CcSEcCtD
Linagliptin—Headache—Erlotinib—kidney cancer	0.000289	0.00199	CcSEcCtD
Linagliptin—Constipation—Vincristine—kidney cancer	0.000289	0.00199	CcSEcCtD
Linagliptin—Pain in extremity—Doxorubicin—kidney cancer	0.000289	0.00199	CcSEcCtD
Linagliptin—Cough—Paclitaxel—kidney cancer	0.000287	0.00198	CcSEcCtD
Linagliptin—Diarrhoea—Sorafenib—kidney cancer	0.000284	0.00196	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—EIF5B—kidney cancer	0.000281	0.0143	CbGpPWpGaD
Linagliptin—Immune system disorder—Capecitabine—kidney cancer	0.00028	0.00193	CcSEcCtD
Linagliptin—Arthralgia—Paclitaxel—kidney cancer	0.00028	0.00193	CcSEcCtD
Linagliptin—Myalgia—Paclitaxel—kidney cancer	0.00028	0.00193	CcSEcCtD
Linagliptin—Mediastinal disorder—Capecitabine—kidney cancer	0.000279	0.00193	CcSEcCtD
Linagliptin—Hypersensitivity—Dactinomycin—kidney cancer	0.000279	0.00192	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000278	0.00192	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000277	0.00191	CcSEcCtD
Linagliptin—Constipation—Gemcitabine—kidney cancer	0.000274	0.00189	CcSEcCtD
Linagliptin—Diarrhoea—Sunitinib—kidney cancer	0.000273	0.00188	CcSEcCtD
Linagliptin—DPP4—renal system—kidney cancer	0.000272	0.141	CbGeAlD
Linagliptin—CYP3A4—Aflatoxin B1 metabolism—GSTM1—kidney cancer	0.000271	0.0138	CbGpPWpGaD
Linagliptin—Malnutrition—Capecitabine—kidney cancer	0.00027	0.00186	CcSEcCtD
Linagliptin—Anaphylactic shock—Paclitaxel—kidney cancer	0.000268	0.00185	CcSEcCtD
Linagliptin—Infection—Paclitaxel—kidney cancer	0.000267	0.00184	CcSEcCtD
Linagliptin—DPP4—kidney—kidney cancer	0.000263	0.136	CbGeAlD
Linagliptin—Rash—Sorafenib—kidney cancer	0.000262	0.0018	CcSEcCtD
Linagliptin—Dermatitis—Sorafenib—kidney cancer	0.000262	0.0018	CcSEcCtD
Linagliptin—Back pain—Capecitabine—kidney cancer	0.000261	0.0018	CcSEcCtD
Linagliptin—Skin disorder—Paclitaxel—kidney cancer	0.000261	0.0018	CcSEcCtD
Linagliptin—Headache—Sorafenib—kidney cancer	0.00026	0.00179	CcSEcCtD
Linagliptin—Diarrhoea—Dactinomycin—kidney cancer	0.000259	0.00178	CcSEcCtD
Linagliptin—Nasopharyngitis—Doxorubicin—kidney cancer	0.000258	0.00178	CcSEcCtD
Linagliptin—DPP4—cortex of kidney—kidney cancer	0.000256	0.132	CbGeAlD
Linagliptin—DPP4—Peptide hormone metabolism—POMC—kidney cancer	0.000253	0.0129	CbGpPWpGaD
Linagliptin—Rash—Sunitinib—kidney cancer	0.000252	0.00174	CcSEcCtD
Linagliptin—Dermatitis—Sunitinib—kidney cancer	0.000252	0.00173	CcSEcCtD
Linagliptin—CYP3A4—Codeine and Morphine Metabolism—ABCB1—kidney cancer	0.000251	0.0128	CbGpPWpGaD
Linagliptin—Headache—Sunitinib—kidney cancer	0.00025	0.00173	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—CUL7—kidney cancer	0.00025	0.0127	CbGpPWpGaD
Linagliptin—Hypersensitivity—Vincristine—kidney cancer	0.000249	0.00172	CcSEcCtD
Linagliptin—Pancreatitis—Doxorubicin—kidney cancer	0.000245	0.00169	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000244	0.00169	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—HSPA9—kidney cancer	0.000239	0.0121	CbGpPWpGaD
Linagliptin—Rash—Dactinomycin—kidney cancer	0.000238	0.00164	CcSEcCtD
Linagliptin—Cough—Capecitabine—kidney cancer	0.000235	0.00162	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000232	0.0016	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000232	0.0016	CcSEcCtD
Linagliptin—Diarrhoea—Vincristine—kidney cancer	0.000231	0.00159	CcSEcCtD
Linagliptin—Myalgia—Capecitabine—kidney cancer	0.00023	0.00158	CcSEcCtD
Linagliptin—Arthralgia—Capecitabine—kidney cancer	0.00023	0.00158	CcSEcCtD
Linagliptin—Constipation—Paclitaxel—kidney cancer	0.000229	0.00158	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000228	0.00157	CcSEcCtD
Linagliptin—Weight increased—Doxorubicin—kidney cancer	0.000227	0.00157	CcSEcCtD
Linagliptin—Infestation NOS—Doxorubicin—kidney cancer	0.000223	0.00153	CcSEcCtD
Linagliptin—Infestation—Doxorubicin—kidney cancer	0.000223	0.00153	CcSEcCtD
Linagliptin—Diarrhoea—Gemcitabine—kidney cancer	0.000219	0.00151	CcSEcCtD
Linagliptin—Infection—Capecitabine—kidney cancer	0.000219	0.00151	CcSEcCtD
Linagliptin—Urinary tract infection—Doxorubicin—kidney cancer	0.000216	0.00149	CcSEcCtD
Linagliptin—Skin disorder—Capecitabine—kidney cancer	0.000214	0.00147	CcSEcCtD
Linagliptin—Urticaria—Paclitaxel—kidney cancer	0.000213	0.00147	CcSEcCtD
Linagliptin—Rash—Vincristine—kidney cancer	0.000213	0.00147	CcSEcCtD
Linagliptin—CYP3A4—Irinotecan Pathway—BCHE—kidney cancer	0.000213	0.0108	CbGpPWpGaD
Linagliptin—Dermatitis—Vincristine—kidney cancer	0.000213	0.00147	CcSEcCtD
Linagliptin—Headache—Vincristine—kidney cancer	0.000212	0.00146	CcSEcCtD
Linagliptin—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—kidney cancer	0.00021	0.0107	CbGpPWpGaD
Linagliptin—Rash—Gemcitabine—kidney cancer	0.000202	0.00139	CcSEcCtD
Linagliptin—Dermatitis—Gemcitabine—kidney cancer	0.000202	0.00139	CcSEcCtD
Linagliptin—Headache—Gemcitabine—kidney cancer	0.000201	0.00138	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000201	0.00138	CcSEcCtD
Linagliptin—Hypersensitivity—Paclitaxel—kidney cancer	0.000198	0.00136	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—MUC4—kidney cancer	0.000195	0.00989	CbGpPWpGaD
Linagliptin—Gastrointestinal disorder—Capecitabine—kidney cancer	0.00019	0.00131	CcSEcCtD
Linagliptin—Constipation—Capecitabine—kidney cancer	0.000188	0.0013	CcSEcCtD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—PGK1—kidney cancer	0.000187	0.00952	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—ST3GAL2—kidney cancer	0.000185	0.00941	CbGpPWpGaD
Linagliptin—Diarrhoea—Paclitaxel—kidney cancer	0.000184	0.00127	CcSEcCtD
Linagliptin—DPP4—Peptide hormone metabolism—CTNNB1—kidney cancer	0.000181	0.0092	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—EEF2—kidney cancer	0.000181	0.0092	CbGpPWpGaD
Linagliptin—Immune system disorder—Doxorubicin—kidney cancer	0.00018	0.00124	CcSEcCtD
Linagliptin—Mediastinal disorder—Doxorubicin—kidney cancer	0.00018	0.00124	CcSEcCtD
Linagliptin—ABCB1—Allograft Rejection—LRRK2—kidney cancer	0.000177	0.00902	CbGpPWpGaD
Linagliptin—Urticaria—Capecitabine—kidney cancer	0.000175	0.00121	CcSEcCtD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—NDRG1—kidney cancer	0.000174	0.00885	CbGpPWpGaD
Linagliptin—Malnutrition—Doxorubicin—kidney cancer	0.000174	0.0012	CcSEcCtD
Linagliptin—Rash—Paclitaxel—kidney cancer	0.000169	0.00117	CcSEcCtD
Linagliptin—Dermatitis—Paclitaxel—kidney cancer	0.000169	0.00117	CcSEcCtD
Linagliptin—Back pain—Doxorubicin—kidney cancer	0.000168	0.00116	CcSEcCtD
Linagliptin—Headache—Paclitaxel—kidney cancer	0.000168	0.00116	CcSEcCtD
Linagliptin—Hypersensitivity—Capecitabine—kidney cancer	0.000162	0.00112	CcSEcCtD
Linagliptin—CYP3A4—Tryptophan metabolism—ALDH1A1—kidney cancer	0.000161	0.00817	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—CA9—kidney cancer	0.000159	0.0081	CbGpPWpGaD
Linagliptin—Cough—Doxorubicin—kidney cancer	0.000152	0.00105	CcSEcCtD
Linagliptin—Diarrhoea—Capecitabine—kidney cancer	0.000151	0.00104	CcSEcCtD
Linagliptin—Myalgia—Doxorubicin—kidney cancer	0.000148	0.00102	CcSEcCtD
Linagliptin—Arthralgia—Doxorubicin—kidney cancer	0.000148	0.00102	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000147	0.00101	CcSEcCtD
Linagliptin—Anaphylactic shock—Doxorubicin—kidney cancer	0.000142	0.000979	CcSEcCtD
Linagliptin—Infection—Doxorubicin—kidney cancer	0.000141	0.000972	CcSEcCtD
Linagliptin—Rash—Capecitabine—kidney cancer	0.000139	0.000957	CcSEcCtD
Linagliptin—Dermatitis—Capecitabine—kidney cancer	0.000139	0.000956	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—MME—kidney cancer	0.000139	0.00705	CbGpPWpGaD
Linagliptin—Headache—Capecitabine—kidney cancer	0.000138	0.000951	CcSEcCtD
Linagliptin—Skin disorder—Doxorubicin—kidney cancer	0.000138	0.000951	CcSEcCtD
Linagliptin—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—kidney cancer	0.000137	0.00698	CbGpPWpGaD
Linagliptin—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—kidney cancer	0.000133	0.00675	CbGpPWpGaD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—kidney cancer	0.00013	0.00659	CbGpPWpGaD
Linagliptin—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000129	0.000892	CcSEcCtD
Linagliptin—DPP4—Metabolism of proteins—HSPD1—kidney cancer	0.000129	0.00655	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—RPL14—kidney cancer	0.000129	0.00655	CbGpPWpGaD
Linagliptin—CYP3A4—Estrogen metabolism—GSTM1—kidney cancer	0.000127	0.00648	CbGpPWpGaD
Linagliptin—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000123	0.000845	CcSEcCtD
Linagliptin—Constipation—Doxorubicin—kidney cancer	0.000121	0.000837	CcSEcCtD
Linagliptin—CYP3A4—Estrogen metabolism—CYP1A1—kidney cancer	0.000121	0.00614	CbGpPWpGaD
Linagliptin—CYP3A4—Irinotecan Pathway—APC—kidney cancer	0.000116	0.00588	CbGpPWpGaD
Linagliptin—Urticaria—Doxorubicin—kidney cancer	0.000113	0.000778	CcSEcCtD
Linagliptin—CYP3A4—Xenobiotics—CYP1A1—kidney cancer	0.000111	0.00564	CbGpPWpGaD
Linagliptin—CYP3A4—Tamoxifen metabolism—CYP1A1—kidney cancer	0.000107	0.00543	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—ACHE—kidney cancer	0.000106	0.0054	CbGpPWpGaD
Linagliptin—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.000105	0.00535	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—EIF4EBP1—kidney cancer	0.000105	0.00534	CbGpPWpGaD
Linagliptin—Hypersensitivity—Doxorubicin—kidney cancer	0.000105	0.000721	CcSEcCtD
Linagliptin—CYP3A4—Biological oxidations—ACY1—kidney cancer	0.000102	0.00519	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—IL13—kidney cancer	0.000101	0.00515	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—PAX6—kidney cancer	0.000101	0.00514	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—CTSD—kidney cancer	0.000101	0.00512	CbGpPWpGaD
Linagliptin—Diarrhoea—Doxorubicin—kidney cancer	9.71e-05	0.00067	CcSEcCtD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—kidney cancer	9.54e-05	0.00485	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—BCHE—kidney cancer	9.26e-05	0.00471	CbGpPWpGaD
Linagliptin—Rash—Doxorubicin—kidney cancer	8.95e-05	0.000617	CcSEcCtD
Linagliptin—Dermatitis—Doxorubicin—kidney cancer	8.94e-05	0.000617	CcSEcCtD
Linagliptin—Headache—Doxorubicin—kidney cancer	8.89e-05	0.000613	CcSEcCtD
Linagliptin—CYP3A4—renal system—kidney cancer	8.87e-05	0.0458	CbGeAlD
Linagliptin—CYP3A4—kidney—kidney cancer	8.57e-05	0.0443	CbGeAlD
Linagliptin—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	8.28e-05	0.00421	CbGpPWpGaD
Linagliptin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	7.89e-05	0.00401	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—IGF2—kidney cancer	7.17e-05	0.00365	CbGpPWpGaD
Linagliptin—ABCB1—nephron tubule—kidney cancer	6.9e-05	0.0357	CbGeAlD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—kidney cancer	6.89e-05	0.0035	CbGpPWpGaD
Linagliptin—ABCB1—renal system—kidney cancer	6.28e-05	0.0324	CbGeAlD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—HIF1A—kidney cancer	6.16e-05	0.00313	CbGpPWpGaD
Linagliptin—ABCB1—kidney—kidney cancer	6.07e-05	0.0314	CbGeAlD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—JUND—kidney cancer	5.95e-05	0.00302	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—APAF1—kidney cancer	5.95e-05	0.00302	CbGpPWpGaD
Linagliptin—ABCB1—cortex of kidney—kidney cancer	5.91e-05	0.0305	CbGeAlD
Linagliptin—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	5.8e-05	0.00295	CbGpPWpGaD
Linagliptin—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	5.7e-05	0.0029	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—kidney cancer	5.64e-05	0.00287	CbGpPWpGaD
Linagliptin—ABCB1—gonad—kidney cancer	5.63e-05	0.0291	CbGeAlD
Linagliptin—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	5.59e-05	0.00284	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—RYR1—kidney cancer	5.53e-05	0.00281	CbGpPWpGaD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—kidney cancer	4.95e-05	0.00252	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ACHE—kidney cancer	4.9e-05	0.00249	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—POMC—kidney cancer	4.78e-05	0.00243	CbGpPWpGaD
Linagliptin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	4.61e-05	0.00234	CbGpPWpGaD
Linagliptin—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	4.55e-05	0.00231	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—kidney cancer	4.51e-05	0.00229	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—JUNB—kidney cancer	4.05e-05	0.00206	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PAK1—kidney cancer	4.05e-05	0.00206	CbGpPWpGaD
Linagliptin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—kidney cancer	3.79e-05	0.00193	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—EGR1—kidney cancer	3.78e-05	0.00192	CbGpPWpGaD
Linagliptin—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	3.74e-05	0.0019	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—JUN—kidney cancer	3.72e-05	0.00189	CbGpPWpGaD
Linagliptin—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	3.44e-05	0.00175	CbGpPWpGaD
Linagliptin—DPP4—Metabolism of proteins—CTNNB1—kidney cancer	3.41e-05	0.00174	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	3.32e-05	0.00169	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—IL2—kidney cancer	3.31e-05	0.00168	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	3.29e-05	0.00167	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTT1—kidney cancer	3.29e-05	0.00167	CbGpPWpGaD
Linagliptin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—kidney cancer	3.25e-05	0.00165	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ATP7B—kidney cancer	3.18e-05	0.00162	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC5A3—kidney cancer	3.18e-05	0.00162	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—ANXA2—kidney cancer	3.18e-05	0.00162	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—PTGS1—kidney cancer	3.08e-05	0.00157	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ACY1—kidney cancer	2.83e-05	0.00144	CbGpPWpGaD
Linagliptin—ABCB1—Allograft Rejection—VEGFA—kidney cancer	2.81e-05	0.00143	CbGpPWpGaD
Linagliptin—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	2.78e-05	0.00142	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PDHB—kidney cancer	2.41e-05	0.00122	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	2.32e-05	0.00118	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTP1—kidney cancer	2.28e-05	0.00116	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CCBL1—kidney cancer	2.26e-05	0.00115	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	2.25e-05	0.00114	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—GSTM1—kidney cancer	2.09e-05	0.00106	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	2.06e-05	0.00105	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	1.98e-05	0.00101	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GLIPR1—kidney cancer	1.96e-05	0.000999	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PPAT—kidney cancer	1.96e-05	0.000999	CbGpPWpGaD
Linagliptin—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	1.96e-05	0.000995	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—APRT—kidney cancer	1.83e-05	0.000928	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—FH—kidney cancer	1.83e-05	0.000928	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	1.82e-05	0.000926	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	1.8e-05	0.000916	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	1.76e-05	0.000896	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ACY1—kidney cancer	1.75e-05	0.000888	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GPC3—kidney cancer	1.72e-05	0.000873	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.68e-05	0.000852	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CA2—kidney cancer	1.67e-05	0.000849	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	1.67e-05	0.000848	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ALAD—kidney cancer	1.63e-05	0.000827	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.62e-05	0.000823	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	1.59e-05	0.000809	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ST3GAL2—kidney cancer	1.59e-05	0.000808	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	1.59e-05	0.000808	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	1.58e-05	0.000801	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ALDH1A1—kidney cancer	1.55e-05	0.000789	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	1.54e-05	0.000781	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PGK1—kidney cancer	1.49e-05	0.000757	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SLC5A3—kidney cancer	1.49e-05	0.000757	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PDHB—kidney cancer	1.48e-05	0.000755	CbGpPWpGaD
Linagliptin—CYP3A4—Biological oxidations—POMC—kidney cancer	1.48e-05	0.000752	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—LDHB—kidney cancer	1.46e-05	0.000742	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CCBL1—kidney cancer	1.4e-05	0.00071	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	1.39e-05	0.000705	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	1.31e-05	0.000667	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	1.28e-05	0.000649	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CA9—kidney cancer	1.27e-05	0.000643	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	1.25e-05	0.000635	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PPAT—kidney cancer	1.21e-05	0.000615	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GLIPR1—kidney cancer	1.21e-05	0.000615	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	1.18e-05	0.0006	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—FH—kidney cancer	1.12e-05	0.000572	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—APRT—kidney cancer	1.12e-05	0.000572	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	1.08e-05	0.000551	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CRABP1—kidney cancer	1.08e-05	0.000547	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GPC3—kidney cancer	1.06e-05	0.000538	CbGpPWpGaD
Linagliptin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	1.05e-05	0.000533	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CA2—kidney cancer	1.03e-05	0.000523	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ALAD—kidney cancer	1e-05	0.00051	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ITPR2—kidney cancer	1e-05	0.000509	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ST3GAL2—kidney cancer	9.78e-06	0.000498	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ALDH1A1—kidney cancer	9.56e-06	0.000486	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PGK1—kidney cancer	9.17e-06	0.000466	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SLC5A3—kidney cancer	9.17e-06	0.000466	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTT1—kidney cancer	9.12e-06	0.000464	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—ACHE—kidney cancer	9.12e-06	0.000464	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—LDHB—kidney cancer	8.99e-06	0.000457	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SCARB1—kidney cancer	8.63e-06	0.000439	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PTGS1—kidney cancer	8.55e-06	0.000435	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PSMD7—kidney cancer	8.38e-06	0.000426	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—BCHE—kidney cancer	7.95e-06	0.000404	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SLC5A5—kidney cancer	7.85e-06	0.000399	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CA9—kidney cancer	7.79e-06	0.000396	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—SLC2A1—kidney cancer	7.58e-06	0.000385	CbGpPWpGaD
Linagliptin—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	7.23e-06	0.000368	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CRABP1—kidney cancer	6.63e-06	0.000337	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTP1—kidney cancer	6.32e-06	0.000321	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ITPR2—kidney cancer	6.16e-06	0.000313	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—GSTM1—kidney cancer	5.81e-06	0.000295	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ACHE—kidney cancer	5.62e-06	0.000286	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTT1—kidney cancer	5.62e-06	0.000286	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—CYP1A1—kidney cancer	5.51e-06	0.00028	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SCARB1—kidney cancer	5.32e-06	0.00027	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PTGS1—kidney cancer	5.27e-06	0.000268	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PSMD7—kidney cancer	5.16e-06	0.000263	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—BCHE—kidney cancer	4.9e-06	0.000249	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SLC5A5—kidney cancer	4.84e-06	0.000246	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—SLC2A1—kidney cancer	4.67e-06	0.000237	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—POMC—kidney cancer	4.11e-06	0.000209	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTP1—kidney cancer	3.89e-06	0.000198	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—ABCB1—kidney cancer	3.69e-06	0.000187	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—GSTM1—kidney cancer	3.58e-06	0.000182	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—CYP1A1—kidney cancer	3.39e-06	0.000173	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PTGS2—kidney cancer	3.28e-06	0.000167	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PTEN—kidney cancer	2.86e-06	0.000145	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—POMC—kidney cancer	2.53e-06	0.000129	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PTGS2—kidney cancer	2.02e-06	0.000103	CbGpPWpGaD
Linagliptin—ABCB1—Metabolism—PIK3CA—kidney cancer	2.01e-06	0.000102	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PTEN—kidney cancer	1.76e-06	8.95e-05	CbGpPWpGaD
Linagliptin—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.24e-06	6.31e-05	CbGpPWpGaD
